1 / 5

Head-to-head Study: ビルダグリプチン vs グリメピリド メトフォルミンへの追加投与（ 1 年中間解析）

Head-to-head Study: ビルダグリプチン vs グリメピリド メトフォルミンへの追加投与（ 1 年中間解析）.

mannix-fitzpatrick
Download Presentation

Head-to-head Study: ビルダグリプチン vs グリメピリド メトフォルミンへの追加投与（ 1 年中間解析）

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Head-to-head Study: ビルダグリプチン vs グリメピリドメトフォルミンへの追加投与（1年中間解析） Study purpose: to demonstrate long-term efficacy and safety of add-on therapy with vildagliptin vs glimepiride in patients with T2DM inadequately controlled with ongoing metformin monotherapy in a randomized, double-blind, multicenter study Interim analysis: to demonstrate non-inferiority of vildagliptin vs glimepiride at 1 year Target population: patients with T2DM inadequately controlled on a stable metformin monotherapy (metformin minimum dose 1500 mg/day; baseline HbA1c 6.5–8.5%) n=1396: ビルダグリプチン 50 mg 1日2回+ メトフォルミン N=2789* n=1393: グリメピリド最大6 mg 1日1回+ メトフォルミン Metformin 1-year interim analysis 4 weeks 104 weeks Ferrannini E, et al. Diabetes Obes Metab. 11,2009,, 157

  2. Head-to-head Study: ビルダグリプチン vs グリメピリドメトフォルミンへの追加投与（1年中間解析） Vilda 50 mg bid + Met Vildagliptin 50 mg twice daily + metformin Glim up to 6 mg qd + Met Glimepiride up to 6 mg once daily + metformin Duration: 52 weeksAdd-on to met: vilda vs glim Patients with>1 Hypos (%) Number of Hypoglycemic Events Severe Events (Grade 2 and Suspected Grade 2) n = 1389 1383 1389 1383 1389 1383 Incidence (%) No. of Events No. of Events Between-group difference in adjusted mean change from BL at 52 weeks: 0.09% NI: 97.5% CI (0.02,0.16) Body Weight (kg) −1.8 kgdifference Mean HbA1c (%) Time (Weeks) Time (Weeks) Ferrannini E, et al. Diabetes Obes Metab. 11,2009,, 157

  3. Vildagliptin better Vildagliptin worse ビルダグリプチン　心・脳血管安全性評価メタ解析（PⅢ-25試験 50mg qd N=1393, 50mg bid N=6116） Incidences and Odds Ratios for Adjudicated CCV Events by Treatment 　・CCV events: ACS, TIA, Stroke, and CCV death Odds Ratio 　ﾋﾞﾙﾀﾞｸﾞﾘﾌﾟﾁﾝAll comparators M-H RR(95% CI) n / N (%) n / N (%) Vilda 50 mg qd 10/1393 (0.72) 14/1555 (0.90) 0.88 (0.37 - 2.11) Vilda 50 mg bid 81/6116 (1.32) 80/4872 (1.64) 0.84 (0.62 - 1.14) 0.1 1 10 Data were pooled from 25 Phase III studies of vildagliptin, used either as monotherapy or combination therapy, with durations of 12 weeks to ≥2 years. The safety of vildagliptin [50 mg qd (N = 1393) or 50 mg bid (N = 6116)] was assessed relative to a pool of all comparators [both placebo and active comparators (N = 6061)]. Diabetes, Obesity and Metabolism 2010 12: 485

  4. ビルダグリプチンとグリメピリドの グルカゴンへの影響（2年間の検討） 5 4 3 2 ビルダグリプチン (n=137) 1 0 グリメピリド (n=121) グルカゴン AUC0-2hr(pmol.hr/L) -1 -2 -3 Baseline glucagon AUC0-2hr：66.6±2.3 pmol.hr/L -4 * -5 P<0.001（vs ｸﾞﾘﾒﾋﾟﾘﾄﾞ） メトホルミンでコントロール不十分な2型糖尿病患者を対象に、グルカゴンへの影響をグリメピリドとビルダグリプチン50mg1日2回とで比較検討した。 Ahren B, et al. Diabetes Care 33:730–732, 2010

More Related